Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis

NCT01664637 is registered in ClinicalTrials.gov with Tranzyme, Inc. as lead sponsor.

NCT NCT01664637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01664637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Lead sponsor
Tranzyme, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2012
Completion date
February 28, 2013
Enrollment
120 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic gastroparesis